NCT07167758 - A Study Evaluating TRIV-509 in Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

June 30, 2027

Conditions

Atopic Dermatitis

Interventions

DRUG

TRIV-509

TRIV-509 (Subcutaneous injection)

DRUG

Placebo

Drug: Placebo (Matching Placebo subcutaneous injection)

Trial Locations (15)

17011

RECRUITING

Triveni Bio Site #1, Camp Hill

17271

RECRUITING

Triveni Bio Site #11, Fountain Valley

33016

RECRUITING

Triveni Bio Site #3, Miami

33607

RECRUITING

Triveni Bio Site #7, Tampa

33609

RECRUITING

Triveni Bio Site #9, Tampa

46250

RECRUITING

Triveni Bio Site #6, Indianapolis

46617

RECRUITING

Triveni Bio Site #10, South Bend

75230

RECRUITING

Triveni Bio Site #5, Dallas

75254

RECRUITING

Triveni Bio Site #2, Dallas

84663

RECRUITING

Triveni Bio Site #14, Springville

92123

RECRUITING

Triveni Bio Site #4, San Diego

99202

RECRUITING

Triveni Bio Site #8, Spokane

L1S 7K8

RECRUITING

Triveni Bio Site #13, Ajax

L2H 1H5

RECRUITING

Triveni Bio Site #12, Niagara Falls

M2N 3A6

RECRUITING

Triveni Bio Site #15, North York